

New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

Nov 15, 2019

Source URL: <https://prod1.novartis.com/us-en/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-tmca-approved-fda-reduce-frequency-pain-crisis-individuals-living-sickle-cell-disease-0>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/new-novartis-medicine-adakveo-crizanlizumab-tmca-approved-fda-reduce-frequency-pain-crisis-individuals-living-sickle-cell-disease-0>